4 July 2017 in American Journal of Transplantation
Early subclinical inflammation in kidney transplants is associated with later graft fibrosis and dysfunction. Regulatory T cells (Tregs) can reverse established inflammation in animal models. We conducted a pilot safety and feasibility trial of autologous Treg cell therapy in three kidney transplant recipients with subclinical inflammation noted on 6‐month surveillance biopsies. Tregs were purified from peripheral blood and polyclonally expanded ex vivo using medium containing deuterated glucose to label the cells. All patients received a single infusion of ~320 × 106 (319, 321, and 363.8 × 106) expanded Tregs. Persistence of the infused Tregs was tracked. Graft inflammation was monitored with follow‐up biopsies and urinary biomarkers. Nearly 1 × 109 (0.932, 0.956, 1.565 × 109) Tregs were successfully manufactured for each patient. There were no infusion reactions or serious therapy‐related adverse events. The infused cells demonstrated patterns of persistence and stability similar to those observed in non‐immunosuppressed subjects receiving the same dose of Tregs. Isolation and expansion of Tregs is feasible in kidney transplant patients on immunosuppression. Infusion of these cells was safe and well tolerated. Future trials will test the efficacy of polyclonal and donor alloantigen‐reactive Tregs for the treatment of inflammation in kidney transplants.
17 December 2020 in American Journal of Transplantation
Interleukin‐6 (IL‐6) is a proinflammatory cytokine and key regulator of Treg: T effector cell (Teff) balance. We hypothesized that IL‐6 blockade with tocilizumab, a monoclonal antibody to IL‐6R, would increase Tregs, dampen Teff function, and control graft inflammation. We conducted a randomized controlled clinical trial (2014‐2018) of clinically stable kidney transplant recipients on calcineurin inhibitor, mycophenolate mofetil and prednisone, with subclinical graft inflammation noted on surveillance biopsies during the first year post‐transplant. Subjects received tocilizumab (8 mg/kg IV every 4 weeks; 6 doses; n=16) or no treatment (controls; n=14) on top of usual maintenance immunosuppression. Kidney biopsies pre‐ and post‐treatment were analyzed using Banff criteria. Blood was analyzed for serum cytokines, Treg frequencies, and T cell effector molecule expression (IFN‐γ, IL‐17, granzyme B) post‐stimulation ex vivo. Tocilizumab‐treated subjects were more likely to show improved Banff ti‐score (62.5% vs. 21.4%, p=0.03), increased Treg frequency (3.6±1.7% vs. 7.1±5.5%, p=0.0168), and a blunted Teff cytokine response compared to controls. Changes in Banff i‐ and t‐scores were not significantly different. The treatment was relatively well‐tolerated with no patient deaths or graft loss. Blockade of IL‐6 is a novel and promising treatment option to regulate the T cell alloimmune response in kidney transplant recipients. NCT02108600
29 September 2020 in Transplant Infectious Disease
4 October 2022 in Journal of the American Society of Nephrology
Significance Statement: Peritransplant TNF blockade with infliximab should not be used in recipients of deceased-donor kidney transplants due to lack of efficacy and an increased incidence of BK virus infection, according to results of a randomized controlled clinical trial. Our results underscore the need for properly controlled and powered trials to avoid falsely accepting unproven therapeutics and reporting incorrect low adverse event rates derived from small, uncontrolled experiments. Background: Ischemia-reperfusion (IR) of a kidney transplant (KTx) upregulates TNF α production that amplifies allograft inflammation and may negatively affect transplant outcomes. Methods: We tested the effects of blocking TNF peri-KTx via a randomized, double-blind, placebo-controlled, 15-center, phase 2 clinical trial. A total of 225 primary transplant recipients of deceased-donor kidneys (KTx; 38.2% Black/African American, 44% White) were randomized to receive intravenous infliximab (IFX) 3 mg/kg or saline placebo (PLBO) initiated before kidney reperfusion. All patients received rabbit anti-thymocyte globulin induction and maintenance immunosuppression (IS) with tacrolimus, mycophenolate mofetil, and prednisone. The primary end point was the difference between groups in mean 24-month eGFR. Results: There was no difference in the primary end point of 24-month eGFR between IFX (52.45 ml/min per 1.73 m 2 ; 95% CI, 48.38 to 56.52) versus PLBO (57.35 ml/min per 1.73 m 2 ; 95% CI, 53.18 to 61.52; P =0.1). There were no significant differences between groups in rates of delayed graft function, biopsy-proven acute rejection (BPAR), development of de novo donor-specific antibodies, or graft loss/death. Immunosuppression did not differ, and day 7 post-KTx plasma analyses showed approximately ten-fold lower TNF ( P <0.001) in IFX versus PLBO. BK viremia requiring IS change occurred more frequently in IFX (28.9%) versus PLBO (13.4%; P =0.004), with a strong trend toward higher rates of BKV nephropathy in IFX (13.3%) versus PLBO (4.9%; P =0.06). Conclusions: IFX induction therapy does not benefit recipients of kidney transplants from deceased donors on this IS regimen. Because the intervention unexpectedly increased rates of BK virus infections, our findings underscore the complexities of targeting peritransplant inflammation as a strategy to improve KTx outcomes. Clinical Trial registry name and registration number: clinicaltrials.gov (NCT02495077).
27 August 2013 in Transplantation
Background Urinary tract infections (UTIs) are common after kidney transplantation, with limited data to guide antibiotic prophylaxis. Methods Retrospective single-center study comparing sulfamethoxazole-trimethoprim 800/160 mg (SMZ/TMP) daily for 30 days followed by Monday, Wednesday, Friday for an additional 5 months (Group 1) versus SMZ/TMP Monday, Wednesday, Friday for 6 months plus ciprofloxacin 250 mg twice daily for 30 days (Group 2) on UTI incidence after kidney transplantation. Results There were 106 and 130 patients in Groups 1 and 2, respectively. Demographics and transplant characteristics were well matched, except for more patients in Group 2 on corticosteroid maintenance. At 1 year, more patients in Group 1 developed UTIs (23.6% vs. 10.8%; P=0.01) and the mean time to first UTI was shorter (96.6±79.5 vs. 168±89.7 days; P=0.01). UTIs caused by Enterococcus species were higher in Group 2 (28.6% vs. 4%; P=0.047) with enteric gram-negative bacilli accounting for the remaining infections. There was a similar incidence of enteric gram-negative antibiotic resistance to SMZ/TMP (75% vs. 80%; P=1.00) and ciprofloxacin (16.7% vs. 30%; P=0.39) in Groups 1 and 2. For Groups 1 and 2, the proportion of first UTIs requiring hospitalization was 48.9% vs. 40.6%, respectively (P=0.62). Female gender was a UTI risk factor (hazard ratio, 3.5; 95% confidence interval, 1.78–6.8; P=0.0003). Conclusions The addition of a 30-day course of ciprofloxacin lowered the incidence of UTI; randomized prospective studies are needed to confirm the safety and efficacy of this approach.
1 December 2022 in American Journal of Transplantation